Profile

MD, Cornell University
MS, Vassar College




A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
03/13/2014 - 03/12/2019 (PI)
Celldex Therapeutics, Inc.


A Randomized, Multicenter, Double-blind, Placebo-controlled comparison of chemotherapy
08/29/2012 - 02/28/2019 (PI)
Genentech, Inc.


A Randomized, 3 Arm, Multi-Center, Phase III Study to Evaluate the Efficacy and the Safety or T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-Placebo (Blinded for Pertuzumab), versus
11/23/2010 - 05/11/2016 (PI)
Genentech, Inc.


A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMABMCC-DM1 VS. CAPECITABINE + LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC
02/23/2009 - 11/21/2012 (PI)
Genentech, Inc.


A Phase III Randomized Double Blind Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Vs Placebo + Trastuzumab+ Docetaxel in Previously
02/23/2009 - 03/31/2012 (PI)
Genentech, Inc.


Phase II Multi-Center, Randomized, Blinded Placebo-Controlled Trial of Carboplatin & Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallo
01/14/2008 - 01/13/2012 (PI)
Genentech, Inc.


A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG or Placebo in Women With Recurrent Partiality Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or
12/02/2010 - 11/30/2011 (PI)
Amgen, Inc.


CA023: A Randomized Phase II Trial of Weekly vs Every 2 Wk vs Every 3 Wk Administration of ABI-007 in Combination of Bevacizumab in Women with Metastatic Breast
01/25/2007 - 09/23/2011 (PI)
Abraxis Bioscience, Inc.


Phase 3, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices
09/27/2006 - 09/26/2008 (PI)
Nuvelo, Inc.

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemother
08/30/2007 - 08/29/2008 (PI)
Eisai Medical Research Institute, Inc.

Showing 10 of 21 results. Show All Results

Olaparib Monotherapy vs. Chemotherapy
12/19/2014 - 12/19/2019 (PI)
Astrazeneca Pharmaceuticals

LEE011
01/19/2016 - 12/31/2018 (PI)
Novartis Pharma Corp

ACRIN 6691 : Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse
11/01/2012 - 11/01/2013 (PI)
Amer College of Radiology NIH-NCI



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Abbas O, Reddy K, Demierre MF, Blanchard RA, Mahalingam M. Epidermotropic metastatic mucoepidermoid carcinoma. Am J Dermatopathol. 2010 Jul; 32(5):505-8.View Related Profiles. PMID: 20489572; DOI: 10.1097/DAD.0b013e3181c956e1;.
     
  2. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11(2):R18.View Related Profiles. PMID: 19320967; PMCID: PMC2688946; DOI: 10.1186/bcr2242;.
     
  3. Stewart JA, Fehrenbacher L, Blanchard RA, Rodriguez GI, Vogel CL, Anavekar P. Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):806. PMID: 28014294.
     
  4. Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las Morenas A, Rosenberg CL. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004 May 15; 22(10):1830-8.View Related Profiles. PMID: 15143075.
     
  5. Tangpricha V, Colon NA, Kaul H, Wang SL, Decastro S, Blanchard RA, Chen TC, Holick MF. Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston. Endocr Pract. 2004 May-Jun; 10(3):292-3.View Related Profiles. PMID: 15310552; PMCID: PMC3098898.
     
  6. Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, Blanchard RA, Rosenberg CL. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer. 2003 Oct 10; 106(6):923-9.View Related Profiles. PMID: 12918071.
     
  7. Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V, Yucel EK, Patriquin L, Eustace S. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging. 2000 Apr; 11(4):343-50. PMID: 10767062.
     
  8. Chinnappan D, Cowan J, Rastogi A, Miller KB, Blanchard R, Wyandt HE. Discrepant cytogenetic and fluorescence in situ hybridization results in a 26-year-old male with early T-cell acute lymphocytic leukemia. Cancer Genet Cytogenet. 1998 Oct 15; 106(2):116-21. PMID: 9797775.
     
  9. Lee VW, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med. 1993 Dec; 34(12):2095-100.View Related Profiles. PMID: 8254394.
     
  10. Hesketh PJ, Tansan S, Caguioa PB, Hesketh A, Blanchard R, DiMartino N, Carney D. Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C. Cancer. 1993 Feb 1; 71(3):717-20. PMID: 8381703.
     
Showing 10 of 11 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.


Contact for Mentoring: